Cargando…
(89)Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding
Cergutuzumab amunaleukin (CEA-IL2v) is an immunocytokine directed against carcinoembryonic antigen (CEA) containing an IL2v-moiety with abolished IL-2 receptor (IL-2R) α binding. We describe the biodistribution and tumor accumulation of (89)Zr-labeled CEA-IL2v. Twenty-four patients with advanced sol...
Autores principales: | van Brummelen, Emilie M.J., Huisman, Marc C., de Wit-van der Veen, Linda J., Nayak, Tapan K., Stokkel, Marcel P.M., Mulder, Emma R., Hoekstra, Otto S., Vugts, Danielle J., Van Dongen, Guus A.M.S., Verheul, Henk M., Evers, Stefan, Tessier, Jean J. L., Saro, Jose, Schellens, Jan H.M., Menke-van der Houven van Oordt, C. Willemien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973872/ https://www.ncbi.nlm.nih.gov/pubmed/29872502 http://dx.doi.org/10.18632/oncotarget.25343 |
Ejemplares similares
-
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
por: Klein, Christian, et al.
Publicado: (2017) -
Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine
por: Cha, Seung E., et al.
Publicado: (2021) -
S41. Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer
por: Klein, C
Publicado: (2014) -
Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation
por: Kujawski, Maciej, et al.
Publicado: (2020) -
(89)Zr-cetuximab PET imaging in patients with advanced colorectal cancer
por: Menke-van der Houven van Oordt, Catharina Willemien, et al.
Publicado: (2015)